Reading...
Play button
Play button
Use LEFT and RIGHT arrow keys to navigate between flashcards;
Use UP and DOWN arrow keys to flip the card;
H to show hint;
A reads text to speech;
147 Cards in this Set
- Front
- Back
- 3rd side (hint)
|
dimenhydrinate
|
Antihistamine-Anticholinergic Agents
simple N/V; N/V due to motion sickness, in combination for more complex N/V interrupts various visceral afferent pathways that stimulate N/V |
Dramamine
|
|
|
diphenhydramine
|
Antihistamine-Anticholinergic Agents
simple N/V; N/V due to motion sickness, in combination for more complex N/V interrupts various visceral afferent pathways that stimulate N/V |
Benadryl
|
|
|
hydroxyzine
|
Antihistamine-Anticholinergic Agents
simple N/V; N/V due to motion sickness, in combination for more complex N/V interrupts various visceral afferent pathways that stimulate N/V |
Atarax
|
|
|
promethazine
|
Antihistamine-Anticholinergic Agents
simple N/V; N/V due to motion sickness, in combination for more complex N/V interrupts various visceral afferent pathways that stimulate N/V |
Phenergan
|
|
|
meclizine
|
Antihistamine-Anticholinergic Agents
simple N/V; N/V due to motion sickness, in combination for more complex N/V interrupts various visceral afferent pathways that stimulate N/V |
Bonine
|
|
|
scopolamine
|
Antihistamine-Anticholinergic Agents
simple N/V; N/V due to motion sickness, in combination for more complex N/V interrupts various visceral afferent pathways that stimulate N/V |
Transderm Scop
|
|
|
chlorpormazine
|
Phenothiazines
simple N/V, mildly emetogenic doses of chemotherapy, in combination for more complex N/V block dopamine receptors, most likely in the CTZ |
Thorazine
|
|
|
perphenazine
|
Phenothiazines
simple N/V, mildly emetogenic doses of chemotherapy, in combination for more complex N/V block dopamine receptors, most likely in the CTZ |
Trilafon
|
|
|
prochlorperazine
|
Phenothiazines
simple N/V, mildly emetogenic doses of chemotherapy, in combination for more complex N/V block dopamine receptors, most likely in the CTZ |
Compazine
|
|
|
droperidol
|
Butyrophenones
PONV, adjunct for CINV blocks dopaminergic stimulation of CTZ |
Inapsine
|
|
|
dexamethasone
|
Corticosteroids
PONV, CINV unknown, inhibition of prostaglandin synthesis may play a role |
Decadron
|
|
|
methylprednisolone
|
Corticosteroids
PONV, CINV unknown, inhibition of prostaglandin synthesis may play a role |
Solu-Medrol
|
|
|
metoclopramide
|
PONV, CINV, delayed CINV
blocks dopaminergic receptors in the CTZ, stimulates cholinergic activity in the gut increasing gut motility, blocks serotonin receptors in intestines |
Reglan
|
|
|
ondansetron
|
Selective Serotonin Antagonists
PONV, CINV, delayed CINV blocks serotonin receptors in medulla, as well as those located along the vagal afferent nerves in the GI tract |
Zofran
|
|
|
dolasetron
|
Selective Serotonin Antagonists
PONV, CINV, delayed CINV blocks serotonin receptors in medulla, as well as those located along the vagal afferent nerves in the GI tract |
Anzemet
|
|
|
granisetron
|
Selective Serotonin Antagonists
PONV, CINV, delayed CINV blocks serotonin receptors in medulla, as well as those located along the vagal afferent nerves in the GI tract |
Kytril
|
|
|
palonsetron
|
Selective Serotonin Antagonists
PONV, CINV, delayed CINV blocks serotonin receptors in medulla, as well as those located along the vagal afferent nerves in the GI tract |
Aloxi
|
|
|
dronabinol
|
Cannabinoids
N/V associated with chemotherapy inhibition of prostaglandins or blocking adrenergic activity |
Marinol
|
|
|
nabilone
|
Cannabinoids
N/V associated with chemotherapy inhibition of prostaglandins or blocking adrenergic activity |
Cesamet
|
|
|
lorazepam
|
Benzodiazepines
anticipatory N/V, rescue N/V causes antegrade amnesia & decreases associated anxiety that may contribute to vomiting |
Ativan
|
|
|
diazepam
|
Benzodiazepines
anticipatory N/V, rescue N/V causes antegrade amnesia & decreases associated anxiety that may contribute to vomiting |
Valium
|
|
|
aprepitant
|
Neurokinin-1 Receptor Antagonist
delayed N/V, secondary to chemotherapy antagonizes neurokinin (which mediates emesis) |
Emend
|
|
|
trimethobenzamide
|
simple N/V, PONV
anticholinergic agent, inhibits stimulation of the CTZ Reserved for pts unresponsive to primary agents |
Tigan
|
|
|
octreotide
|
Hypothalamic Agents
synthetic GH antagonist structurally related to somatostatin |
Sandostatin
|
|
|
pegvisomant
|
Hypothalamic Agents
newest agent that is GH antagonist |
Somavert
|
|
|
protirelin
|
Hypothalamic Agents
|
Thypinone
|
|
|
corticotropin
|
Anterior Pituitary Agents
|
ACTH, Acthar
|
|
|
cosyntropin
|
Anterior Pituitary Agents
|
Cortrosyn
|
|
|
somatrem
|
Anterior Pituitary Agents
|
Protropin
|
|
|
somatropin
|
Anterior Pituitary Agents
|
Genotropin, Humatrope, others
|
|
|
thyrotropin
|
Anterior Pituitary Agents
|
Thyrogen, Thyroid-stimulating hormone (TSH)
|
|
|
desmopressin acetate
|
Posterior Pituitary Agents
most common form of ADH in use |
DDAVP, Stimate
|
|
|
vasopressin
|
Posterior Pituitary Agents
drug for Diabetes Insipidus |
Pitressin
|
|
|
levothyroxine
|
Thyroid Drugs
|
Levothroid, Synthroid, others
|
|
|
liothyronine
|
Thyroid Drugs
|
Cytomel, Triostat
|
|
|
thyroid
|
Thyroid Drugs
|
Armour Thyroid, Westhroid
|
|
|
methimazole
|
Antithyroid Drugs
pregnancy category D - crosses placenta more readily |
Tapazole
|
|
|
potassium iodide
|
Antithyroid Drugs
|
ThyroShield, SSKI
|
|
|
propylthiouracil
|
Antithyroid Drugs
|
PTU
|
|
|
radioactive iodine
|
Antithyroid Drugs
destroys follicular cells w/radiation (contraindicated in pregnancy) |
I-131, RAI
|
|
|
cortisone
|
Short-Acting Glucocorticoids
replacement therapy for adrenal insufficiency & to decrease inflammation & immune responses |
Cortistan, Cortone
|
|
|
hydrocortisone
|
Short-Acting Glucocorticoids
replacement therapy for adrenal insufficiency & to decrease inflammation & immune responses |
Cortef, Hydrocortone, others
|
|
|
methylprednisolone
|
Intermediate-Acting Glucocorticoids
replacement therapy for adrenal insufficiency & to decrease inflammation & immune responses |
Medrol, others
|
|
|
prednisolone
|
Intermediate-Acting Glucocorticoids
replacement therapy for adrenal insufficiency & to decrease inflammation & immune responses |
Delta-Cortef, others
|
|
|
prednisone
|
Intermediate-Acting Glucocorticoids
replacement therapy for adrenal insufficiency & to decrease inflammation & immune responses |
Deltasone, Meticorten, others
|
|
|
triamcinolone
|
Intermediate-Acting Glucocorticoids
replacement therapy for adrenal insufficiency & to decrease inflammation & immune responses |
Aristocort, Kenacort, others
|
|
|
betamethasone
|
Long-Acting Glucocorticoids
replacement therapy for adrenal insufficiency & to decrease inflammation & immune responses |
Celestone
|
|
|
dexamethasone
|
Long-Acting Glucocorticoids
replacement therapy for adrenal insufficiency & to decrease inflammation & immune responses |
Decadron, Dexasone, others
|
|
|
metformin
|
Biguanides
DOC; first line therapy for DMT2 decreases hepatic gluconeogenesis, improves insulin sensitivity, increases glucose utilization by muscle |
Glucophage
|
|
|
nateglinide
|
Insulin Secretagogues: Nonsulfonylureas (Glinides)
Monotherapy or combination therapy for DMT2 Stimulates insulin release from pancreas |
Starlix
|
|
|
repaglinide
|
Insulin Secretagogues: Nonsulfonylureas (Glinides)
Monotherapy or combination therapy for DMT2 Stimulates insulin release from pancreas |
Prandin
|
|
|
chlorpropamide
|
Insulin Secretagogues: Sulfonylureas
Monotherapy or combination therapy for DMT2 Stimulates insulin release from pancreas, enhances beta cell sensitivity to glucose |
Diabinese
|
|
|
tolazamide
|
Insulin Secretagogues: Sulfonylureas
Monotherapy or combination therapy for DMT2 Stimulates insulin release from pancreas, enhances beta cell sensitivity to glucose |
Tolinase
|
|
|
tolbutamide
|
Insulin Secretagogues: Sulfonylureas
Monotherapy or combination therapy for DMT2 Stimulates insulin release from pancreas, enhances beta cell sensitivity to glucose |
Tol-Tab
|
|
|
glyburide
|
Insulin Secretagogues: Sulfonylureas
Monotherapy or combination therapy for DMT2 Stimulates insulin release from pancreas, enhances beta cell sensitivity to glucose |
Diabeta, Micronase
|
|
|
glipizide
|
Insulin Secretagogues: Sulfonylureas
Monotherapy or combination therapy for DMT2 Stimulates insulin release from pancreas, enhances beta cell sensitivity to glucose |
Glucotrol
|
|
|
glimepiride
|
Insulin Secretagogues: Sulfonylureas
Monotherapy or combination therapy for DMT2 Stimulates insulin release from pancreas, enhances beta cell sensitivity to glucose |
Amaryl
|
|
|
pioglitazone
|
Thiazolidinediones
Monotherapy or combination therapy for DMT2 increases receptor sensitivity to insulin, decreases both insulin resistance & hepatic gluconeogenesis |
Actos
|
|
|
rosiglitazone
|
Thiazolidinediones
Monotherapy or combination therapy for DMT2 increases receptor sensitivity to insulin, decreases both insulin resistance & hepatic gluconeogenesis |
Avandia
|
|
|
acarbose
|
Alpha-glucosidase Inhibitors
Adjunct therapy only for DMT2 reduces rate & extent of CHO digestion & absorption |
Precose
|
|
|
miglitol
|
Alpha-glucosidase Inhibitors
Adjunct therapy only for DMT2 reduces rate & extent of CHO digestion & absorption |
Glyset
|
|
|
exenatide
|
Glucagon-like Peptide-1 Agonists
Monotherapy for DMT2, generally considered as adjunct, contraindicated in severe renal dysfunction & pancreatitis. Increase insulin release in the presence of elevated glucose concentrations, decrease glucagon secretion in a glucose-dependent manner & delay gastric emptying |
Byetta
|
|
|
liraglutide
|
Glucagon-like Peptide-1 Agonists
Combination therapy for DMT2, contraindicated in severe renal dysfunction, pancreatitis, & h/o thyroid CA REMS program, Increase insulin release in the presence of elevated glucose concentrations, decrease glucagon secretion in a glucose-dependent manner & delay gastric emptying |
Victoza
|
|
|
sitagliptin
|
Dipeptidyl Peptidase-4 Inhibitor
Monotherapy or combination therapy for DMT2, generally considered adjunct therapy; contraindicated in ESRD inhibit degradation of GIP & GLP-1 |
Januvia
|
|
|
saxagliptin
|
Dipeptidyl Peptidase-4 Inhibitor
Monotherapy or combination therapy for DMT2, generally considered adjunct therapy; contraindicated in ESRD inhibit degradation of GIP & GLP-1 |
Onglyza
|
|
|
linagliptin
|
Dipeptidyl Peptidase-4 Inhibitor
Monotherapy or combination therapy for DMT2, generally considered adjunct therapy inhibit degradation of GIP & GLP-1 |
Tradjenta
|
|
|
pramlintide
|
Amylin Receptor Agonists
Adjunct therapy for DMT1 & T2; contraindicated in pts with hypoglycemic unawareness or gastroparesis Inhibit the degradation of GIP & GLP-1 |
Symlin
|
|
|
glipizide/metformin
|
Combination Hypoglycemics
|
Metaglip
|
|
|
glyburide/metformin
|
Combination Hypoglycemics
|
Glucovance
|
|
|
rosiglitazone/glimepride
|
Combination Hypoglycemics
|
Avandaryl
|
|
|
pioglitazone/metformin
|
Combination Hypoglycemics
|
ACTOplus met
|
|
|
rosiglitazone/metformin
|
Combination Hypoglycemics
|
Avandamet
|
|
|
Insulin Lispro
|
Rapid-Acting Insulin
Onset: 5-15 min Peak: 30-90 min Duration: < 5 hrs |
Humalog
|
|
|
Insulin Aspart
|
Rapid-Acting Insulin
Onset: 5-15 min Peak: 30-90 min Duration: < 5 hrs |
NovaLog
|
|
|
Insulin Glulisine
|
Rapid-Acting Insulin
Onset: 5-15 min Peak: 30-90 min Duration: < 5 hrs |
Apidra
|
|
|
Regular Insulin
|
Short-Acting Insulin
Onset: 0.5-1 hr Peak: 2-4 hrs Duration: 5-7 hrs |
Humulin R
|
|
|
NPH
|
Intermediate-Acting Insulin
Onset: 2-4 hrs Peak: 4-12 hrs Duration: 12-18 hrs |
NPH
|
|
|
Insulin glargine
|
Long-Acting Insulin
Onset: 1.5 hrs Peak: No pronounced peak Duration: 20-24 hrs |
Lantus
|
|
|
Insulin determir
|
Long-Acting Insulin
Onset: 0.8-2 hrs Peak: Relatively flat peak Duration: 5.7-23.2 hrs |
Levemir
|
|
|
Alesse
|
Monophasic OC
Most common; delivers a constant amount of estrogen and progestin in every pill |
|
|
|
Desogen
|
Monophasic OC
Most common; delivers a constant amount of estrogen and progestin in every pill |
|
|
|
Loestrin 1.5/30 Fe
|
Monophasic OC
Most common; delivers a constant amount of estrogen and progestin in every pill |
|
|
|
Lo/Ovral
|
Monophasic OC
Most common; delivers a constant amount of estrogen and progestin in every pill |
|
|
|
Ortho-Cyclen
|
Monophasic OC
Most common; delivers a constant amount of estrogen and progestin in every pill |
|
|
|
Yasmin
|
Monophasic OC
Most common; delivers a constant amount of estrogen and progestin in every pill |
|
|
|
Ortho-Novum 10/11
|
Biphasic OC
Amount of estrogen in each pill remains constant, but the amount of progestin is increased toward the end of the menstrual cycle to better nourish the uterine lining |
|
|
|
Ortho Tri-Cyclen
|
Triphasic OC
Amounts of estrogen and progestin vary in three distinct phases during the 28-day cycle |
|
|
|
Ortho-Novum 7/7/7
|
Triphasic OC
Amounts of estrogen and progestin vary in three distinct phases during the 28-day cycle |
|
|
|
Tri-Levlen
|
Triphasic OC
Amounts of estrogen and progestin vary in three distinct phases during the 28-day cycle |
|
|
|
Triphasil
|
Triphasic OC
Amounts of estrogen and progestin vary in three distinct phases during the 28-day cycle |
|
|
|
Micronor
|
Progestin-Only Minipill
Prevents pregnancy primarily by producing thick, viscous mucus at the entrance to the uterus that discourages penetration by sperm. Also inhibits implantation of a fertilized egg |
|
|
|
Nor-Q.D.
|
Progestin-Only Minipill
Prevents pregnancy primarily by producing thick, viscous mucus at the entrance to the uterus that discourages penetration by sperm. Also inhibits implantation of a fertilized egg |
|
|
|
Ovrette
|
Progestin-Only Minipill
Prevents pregnancy primarily by producing thick, viscous mucus at the entrance to the uterus that discourages penetration by sperm. Also inhibits implantation of a fertilized egg |
|
|
|
Depro-Provera
|
Injection Contraception
Deep IM injection of medroxyprogesterone that provides 3 months of contraception |
|
|
|
etongestrel
|
Implant Concentration
Single rod containing progestin Provides 3 years of protection |
Implanon/Nexplanon
|
|
|
levonorgestrel
|
Implant Concentration
Intrauterine system inserted by healthcare practitioner Provides 3 (Skyla) or 5 years (Mirena) of protection |
Mirena/Skyla
|
|
|
Ortho-Evra
|
Transdermal patch containing both estrogen and progestin
Patch is changed every 7 days for the first 3 weeks, then no patch is used for week 4 |
|
|
|
NuvaRing
|
2 inch in diameter prescriptive vaginal ring of estrogen and progestin
Inserted to provide 3 weeks of protection Removed during week 4, and a new ring is inserted during the first week of the next menstrual cycle |
|
|
|
Mirena
|
Polyethylene cylinder placed in the uterus that releases levonorgestrel
About the size of a quarter and shaped like a T; Mirena acts locally to prevent contraception for 5 years |
|
|
|
Seasonale
|
Extended Regimen OC
combination tablets taken for 84 consecutive days, followed by 7 inert days (without hormones) |
|
|
|
Seasonique
|
Extended Regimen OC
Similar to Seasonale, except low-dose estrogen replaces the inert tablets |
|
|
|
ethinyl estradiol & levonorgestrel
|
Emergency Contraception
One tablet within 72 hours of intercourse, followed by 2 pills 12 hours later |
Preven
|
|
|
levonorgestrel
|
Emergency Contraception
One or two tablet preparation taken within 72 hours of intercourse |
Plan B
|
|
|
carboprost tromethamine
|
Pharmacological Abortion
|
Hemabate
|
|
|
dinoprostone
|
Pharmacological Abortion
|
Cervidil, Prepidil, Prostin E2
|
|
|
methotrexate with misoprostol
|
Pharmacological Abortion
|
|
|
|
mifepristone with misoprostol
|
Pharmacological Abortion
|
Mifeprex
|
|
|
estradiol
|
Estrogen for HT
|
Estraderm, Estrace
|
|
|
estradiol cypionate
|
Estrogen for HT
|
Dep-Gynogen, Depogen
|
|
|
estradiol valerate
|
Estrogen for HT
|
Delestrogen, Duragen-10, Valergen
|
|
|
estrogen, conjugated
|
Estrogen for HT
|
Premarin
|
|
|
estropipate
|
Estrogen for HT
|
Ogen
|
|
|
ethinyl estradiol
|
Estrogen for HT
|
Estinyl, Feminone
|
|
|
medrosyprogesterone
|
Progestin for HT
|
Provera, Cycrin
|
|
|
norethindrone
|
Progestin for HT
|
Micronor, Nor-Q.D.
|
|
|
norethindrone acetate
|
Progestin for HT
|
Norlutate
|
|
|
progesterone micronized
|
Progestin for HT
|
Prometrium
|
|
|
Conjugated estrogen, equine / medroxyprogesterone acetate
|
Estrogen-Progestin for HT
|
Prempro
|
|
|
estradiol/drospirenone
|
Estrogen-Progestin for HT
|
Angeliq
|
|
|
estradiol/norgestimate
|
Estrogen-Progestin for HT
|
Ortho-Prefest
|
|
|
ethinyl estradiol / norethindrone acetate
|
Estrogen-Progestin for HT
|
Femhrt
|
|
|
oxytocin
|
Uterine Stimulants (Oxytocics)
Stimulates uterine contractions; may be used postpartum to control/decrease bleeding |
Pitocin
|
|
|
ergonovine maleate
|
Uterine Stimulants (Oxytocics)
Stimulates uterine contractions; may be used postpartum to control/decrease bleeding |
Ergotrate
|
|
|
methylergonovine maleate
|
Uterine Stimulants (Oxytocics)
Stimulates uterine contractions; may be used postpartum to control/decrease bleeding |
Methergine
|
|
|
carboprost tromethamine
|
Uterine Stimulants (Oxytocics)
Stimulates uterine contractions; may be used postpartum to control/decrease bleeding |
Hemabate
|
|
|
dinoprostone
|
Uterine Stimulants (Oxytocics)
Stimulates uterine contractions; may be used postpartum to control/decrease bleeding |
Cervidil, Prepidil, Prostine E2
|
|
|
misoprostol
|
Uterine Stimulants (Oxytocics)
Stimulates uterine contractions; may be used postpartum to control/decrease bleeding |
Cytotec
|
|
|
terbutaline sulfate
|
Uterine Relaxants (Tocolytics): Beta2-Adrenergic Agonists
Inihibit uterine contractions |
Brethine
|
|
|
danazol
|
Androgens
Androgens and/or testosterone are used for lack of testosterone (hypogonadism) |
Danocrine
|
|
|
fluoxymesterone
|
Androgens
Androgens and/or testosterone are used for lack of testosterone (hypogonadism) |
Halotestin
|
|
|
methyltestosterone
|
Androgens
Androgens and/or testosterone are used for lack of testosterone (hypogonadism) |
Android, Testred
|
|
|
testolactone
|
Androgens
Androgens and/or testosterone are used for lack of testosterone (hypogonadism) |
Teslac
|
|
|
testosterone
|
Androgens
Androgens and/or testosterone are used for lack of testosterone (hypogonadism) |
Androderm, Testim
|
|
|
testosterone cypionate
|
Androgens
Androgens and/or testosterone are used for lack of testosterone (hypogonadism) |
Depotest, Andro-Cyp, Depo-Testosterone
|
|
|
testosterone enanthate
|
Androgens
Androgens and/or testosterone are used for lack of testosterone (hypogonadism) |
Andro L.A., Delatest, Delatestryl
|
|
|
sildenafil
|
Phosphodiesterade (PDE) Inhibitor
Onset: 30 mins Duration: 4 hours Take WITHOUT food |
Viagra
|
|
|
vardenafil
|
Phosphodiesterade (PDE) Inhibitor
Onset: 60 mins Duration: 4 hours Take WITHOUT food |
Levitra
|
|
|
tadalafil
|
Phosphodiesterade (PDE) Inhibitor
Onset: 15 mins Duration: up to 36 hours Take WITH or WITHOUT food |
Cialis
|
|
|
avanafil
|
Phosphodiesterade (PDE) Inhibitor
Onset: 15 mins Duration: up to 36 hours Take WITH or WITHOUT food |
Stendra
|
|
|
doxazosin
|
Agents for BPH: Alpha-Adrenergic Blockers
1st Dose Phenomena: may cause severe hypotension & syncope, tachycardia |
Cardura
|
|
|
prazosin
|
Agents for BPH: Alpha-Adrenergic Blockers
1st Dose Phenomena: may cause severe hypotension & syncope, tachycardia |
Minipress
|
|
|
terazosin
|
Agents for BPH: Alpha-Adrenergic Blockers
1st Dose Phenomena: may cause severe hypotension & syncope, tachycardia |
Hytrin
|
|
|
tamsulosin
|
Agents for BPH: Alpha-Adrenergic Blockers
|
Flomax
|
|
|
Alfuzosin
|
Agents for BPH: Alpha-Adrenergic Blockers
|
Uroxatral
|
|
|
silodosin
|
Agents for BPH: Alpha-Adrenergic Blockers
|
Rapaflo
|
|
|
dutasteride
|
Agents for BPH: 5-Alpha-Reductase Inhibitors
Women must not touch medication |
Avodart
|
|
|
finasteride
|
Agents for BPH: 5-Alpha-Reductase Inhibitors
|
Proscar
|
